E-mail ID : info@iamg.in |
Online Submission |
Click Here For Online Submission |
Instructions for authors |
Genetic Clinics |
Editorial board |
Get Our Newsletter |
Subscribe |
Send Your Feedback |
Feedback Form |
About Us |
IAMG |
Abstract
October-December 2015 | Vol. 8 | Issue 4 | Page No 6-11 | |||
Mendelian Disease Gene Identification and Diagnosticsusing Targeted Next Generation Sequencing | |||
Daniel Trujillano 1∗, Rami Abou Jamra 1 and Arndt Rolfs 1,2 | |||
Centogene AG, Rostock, Germany | Albrecht-Kossel-Institute for Neuroregeneration, Medical University Rostock, Rostock, Germany | |||
Address for Correspondence Email: daniel.trujillano@centogene.com | |||
Abstract During the last few months we have observed for the first time since the introduction of the first massive parallel sequencers in 2007, that the cost of sequencing a human genome has not changed significantly (Figure 1) [Wetterstrand., 2015]. These numbers challenge a trend that has been maintained during years beating Moore’s law, and indicates that in the medium term we should not expect sequencing to be significantly cheaper until the next technological revolution | |||
HTML Full Text | Download PDF |